Table 1. Pilot Clinical Findings in Melanoma.
Therapy | |||||||||
---|---|---|---|---|---|---|---|---|---|
Signaturea | TL-ELNs | Sample No.a | Tumor Location | Time (in months)b | None | Surgery | Chemoe | XRT | Other |
+ | + | 112 | Pancreas | 180c,d | + | Ipi | |||
+ | + | 115 | Lung | 114c,d | + | ||||
+ | + | 116 | Lung | 72c,d | + | + | |||
+ | + | 113 | Lung | 72c | + | + | |||
+ | + | 118 | Pelvic soft tissue | 65c | + | ||||
− | − | 5 | Liver | 36 | + | ||||
− | − | 1 | Brain | 35 | + | + | |||
− | − | 3 | Brain | 30 | + | + | IFN | ||
− | − | 6 | Skinf | 13 | + | ||||
− | − | 7 | Node | 8 | + |
aSee Figure 2c.
bTime (in months) since primary melanoma to death or present date of evaluation.
cp = 0.008 compared to signature − group (exact Wilcoxon rank sum test).
dAlive as of May 1, 2012.
eChemotherapy drugs included: carbo-taxol (1 patient), temozolomide (2 patients), liposomal cytarabine and sagopilone (1 patient each).
fSubcutaneous metastasis.
Abbreviations: Ipi, ipilimumab; IFN, interferon-alfa; XRT, external beam radiation therapy.